(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(-0.18%) $82.66
(0.67%) $1.664
(-0.27%) $2 332.00
(-0.30%) $27.27
(-0.36%) $912.50
(-0.05%) $0.934
(-0.05%) $10.98
(-0.01%) $0.802
(0.00%) $92.32
Live Chart Being Loaded With Signals
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care...
Stats | |
---|---|
Today's Volume | 2.93M |
Average Volume | 2.49M |
Market Cap | 1.68M |
EPS | £0 ( 2023-05-22 ) |
Next earnings date | ( £0 ) 2024-06-29 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | 0 |
ATR14 | £0 (0.00%) |
Nuformix PLC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nuformix PLC Financials
Annual | 2023 |
Revenue: | £0 |
Gross Profit: | £-36 749.00 (0.00 %) |
EPS: | £-0.000800 |
Q2 | 2023 |
Revenue: | £0 |
Gross Profit: | £-18 343.00 (0.00 %) |
EPS: | £-0.000300 |
Q4 | 2022 |
Revenue: | £0 |
Gross Profit: | £-18 406.00 (0.00 %) |
EPS: | £-0.000500 |
Q2 | 2022 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.000600 |
Financial Reports:
No articles found.
Nuformix PLC
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators